Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Raw Materials (2016 - 2019)

Ironwood Pharmaceuticals (IRWD) has disclosed Raw Materials for 4 consecutive years, with $65000.0 as the latest value for Q4 2019.

  • Quarterly Raw Materials changed N/A to $65000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $65000.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $65000.0 for FY2019, N/A changed from the prior year.
  • Raw Materials hit $65000.0 in Q4 2019 for Ironwood Pharmaceuticals, down from $1.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.5 million in Q1 2017 to a low of $65000.0 in Q4 2019.
  • Historically, Raw Materials has averaged $800750.0 across 4 years, with a median of $801500.0 in 2016.
  • Biggest five-year swings in Raw Materials: tumbled 79.64% in 2018 and later surged 378.9% in 2019.
  • Year by year, Raw Materials stood at $1.0 million in 2016, then skyrocketed by 49.8% to $1.5 million in 2017, then crashed by 79.64% to $308000.0 in 2018, then crashed by 78.9% to $65000.0 in 2019.
  • Business Quant data shows Raw Materials for IRWD at $65000.0 in Q4 2019, $1.1 million in Q3 2019, and $1.5 million in Q2 2019.